First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

布鲁顿酪氨酸激酶 伊布替尼 慢性淋巴细胞白血病 套细胞淋巴瘤 医学 滤泡性淋巴瘤 华登氏巨球蛋白血症 肿瘤溶解综合征 中性粒细胞减少症 癌症研究 放射免疫疗法 内科学 淋巴瘤 免疫学 白血病 酪氨酸激酶 毒性 化疗 抗体 受体 单克隆抗体
作者
John F. Seymour,Chan Y. Cheah,Ricardo Parrondo,Meghan C. Thompson,Don A. Stevens,Masa Lasica,Michael L. Wang,Abhijeet Kumar,Judith Trotman,Maan Alwan,Wei Ding,Kunthel By,Bilal Tariq,Xiangmei Chen,Shannon Fabre,Jason C. Paik,Amit Kumar Agarwal,Constantine S. Tam
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4401-4401 被引量:7
标识
DOI:10.1182/blood-2023-180109
摘要

Introduction: BTK inhibitors (BTKis) are approved for chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Disease that progresses on BTKis often has BTK mutations that lead to treatment (tx) resistance; novel BTK-targeting agents that overcome BTKi resistance are needed. BGB-16673 is a heterobifunctional small molecule that binds to BTK and E3 ligase, resulting in BTK degradation via ubiquitination. In preclinical models, BGB-16673 degraded wild-type (WT) BTK and known covalent and noncovalent BTKi-resistant mutant proteins, leading to tumor suppression. Methods: Pts with R/R CLL, WM, MCL, MZL, non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or Richter transformation (RT) were eligible for this open-label, first-in-human, phase 1 trial (BGB-16673-101; NCT05006716). Pts must have received ≥2 prior therapies (≥1 for RT) and have an ECOG performance status of 0-2 and adequate end-organ function. In the US and Australia, pts must have received a covalent BTKi (cBTKi) if approved for their disease. BGB-16673 was dosed daily by mouth in 28-day cycles. Escalation using a Bayesian optimal interval design with 6 dose levels (50-600 mg once daily) is planned. Primary objectives are to assess safety/tolerability and establish the maximum tolerated dose (MTD) and recommended phase 2 dose. Key secondary objectives are to assess pharmacokinetics, pharmacodynamics (PD), and preliminary antitumor activity. Safety was assessed according to CTCAE v5.0 (all pts) and iwCLL hematologic toxicity criteria (pts with CLL). Dose-limiting toxicities (DLTs) were assessed in the first 4 weeks. Response was assessed per Lugano criteria for all except CLL (iwCLL 2018 criteria) and WM (iwWM-6 criteria). Results: As of May 26, 2023, 26 pts (10 CLL, 4 MCL, 2 MZL, 4 WM, 4 FL, 1 DLBCL, 1 RT) were enrolled at 5 dose levels (50 mg, 4; 100 mg, 9; 200 mg, 9; 350 mg, 3; 500 mg, 1). Median age was 70.5 y (range, 25-83). Median number of prior therapies was 3.5 (range, 2-9), including cBTKis (n=21; 10 CLL, 4 WM, 4 MCL, 1 MZL, 1 RT, 1 DLBCL), BCL2 inhibitors (n=12; 9 CLL, 2 WM, 1 RT), and noncovalent BTKis (ncBTKis; n=4; 2 CLL, 1 WM, 1 FL). In CLL, del17p/ TP53 mutation (n=8) and unmutated IGHV (n=7) were frequent. Median follow-up was 3.5 mo (range, 0.2-13.9). MTD was not reached. Treatment-emergent AEs (TEAEs) were reported by 88.5% of pts (grade [gr] ≥3, 46.2%; serious, 38.5%). The most common TEAEs were contusion (30.8%; no gr ≥3), pyrexia (23.1%; no gr ≥3), neutropenia/neutrophil count decreased (23.1%; gr ≥3, 15.4%), and lipase increased (23.1%; gr ≥3, 3.8%; all transient and asymptomatic). No hypertension or atrial fibrillation was observed. One pt died from sepsis with possible disease progression. No discontinuations due to AEs occurred. Two pts had dose reductions due to TEAEs (gr 3 hematuria with urinary tract infection and recurrent urothelial carcinoma and gr 2 arthralgia). One DLT occurred in 1 pt at 200 mg (gr 3 maculopapular rash on day 27; after 5-day dose hold, assigned dose was recommenced with persistent gr 1 rash). BGB-16673 exposure increased in a dose-dependent manner. At steady state with doses ≥50 mg daily, BGB-16673 exposure exceeded the calculated half maximal degradation concentration for WT and cysteine 481-mutated BTK for the dosing interval. Preliminary PD data showed deep, sustained reductions in BTK protein levels in peripheral blood and tumor tissue, even at the lowest dose. Most CLL pts experienced lymphocytosis during the first 3 cycles of tx. Twenty of 26 pts (77%) remain on therapy (discontinuation: 4 progressive disease, 2 withdrawal). Of 18 response-evaluable pts, 12 (67%) responded (5/6 CLL, 1/3 MCL, 2/2 MZL, 3/4 WM, 1/2 FL, 0/1 DLBCL; 1 CR in MCL, all others had PR; Figure), including pts who received a cBTKi (n=10) and an ncBTKi (n=2). Responses started at the lowest dose level. All responders remain in response, the longest responder remaining on tx for 60 weeks. Conclusions: Preliminary data from this ongoing, first-in-human study of the novel BTK degrader BGB-16673 demonstrate a tolerable safety profile and clinical responses in heavily pretreated pts with B-cell malignancies, including those with BTKi-resistant disease. Substantial reductions in BTK protein levels in peripheral blood and tumor tissue were also observed, demonstrating proof-of-concept of a strong, on-target effect.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是老大应助mm采纳,获得10
1秒前
搜集达人应助egg采纳,获得30
1秒前
Nariy完成签到,获得积分10
1秒前
充电宝应助emm采纳,获得10
2秒前
任性铅笔完成签到 ,获得积分10
2秒前
2秒前
2秒前
2秒前
半柚应助sdl采纳,获得10
3秒前
3秒前
六便士发布了新的文献求助10
4秒前
流云完成签到,获得积分10
4秒前
汉堡包应助ff采纳,获得10
5秒前
smottom应助机械师简采纳,获得20
5秒前
小糖发布了新的文献求助10
5秒前
5秒前
SciGPT应助含蓄绿兰采纳,获得10
6秒前
徐徐徐徐发布了新的文献求助10
6秒前
机器发布了新的文献求助10
6秒前
Ava应助guguhuhu采纳,获得10
6秒前
Eon发布了新的文献求助10
7秒前
OrangeLight发布了新的文献求助10
7秒前
wewewew发布了新的文献求助10
9秒前
kunkun发布了新的文献求助10
10秒前
朱迪完成签到 ,获得积分10
11秒前
Emma完成签到 ,获得积分10
11秒前
碧蓝巧荷完成签到 ,获得积分10
11秒前
弗洛洛完成签到 ,获得积分10
12秒前
12秒前
魏冉发布了新的文献求助10
12秒前
13秒前
徐徐徐徐完成签到,获得积分10
14秒前
共享精神应助plant采纳,获得10
14秒前
14秒前
顺利毕业发布了新的文献求助10
15秒前
15秒前
谓之新午完成签到,获得积分10
15秒前
李静发布了新的文献求助10
16秒前
在水一方应助wewewew采纳,获得10
16秒前
lideng完成签到 ,获得积分10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970843
求助须知:如何正确求助?哪些是违规求助? 3515550
关于积分的说明 11178897
捐赠科研通 3250660
什么是DOI,文献DOI怎么找? 1795393
邀请新用户注册赠送积分活动 875828
科研通“疑难数据库(出版商)”最低求助积分说明 805188